Algert Global LLC Cuts Stock Position in ADMA Biologics Inc $ADMA

Key Points

• Algert Global LLC reduced its ownership in ADMA Biologics by 31.8%, selling 86,510 shares and ending the quarter with 185,839 shares valued at approximately $3.69 million.
• ADMA Biologics reported a quarterly earnings per share of $0.15, exceeding estimates, along with a 13.8% year-over-year revenue increase to $121.98 million.
• Institutional investors currently own 75.68% of ADMA Biologics, reflecting significant investor interest in the company as several large investors modified their stakes during the quarter.

Algert Global LLC cut its stake in ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 31.8% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 185,839 shares of the biotechnology company's stock after selling 86,510 shares during the period. Algert Global LLC owned 0.08% of ADMA Biologics worth $3,687,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in ADMA. Cetera Investment Advisers increased its position in shares of ADMA Biologics by 1.3% in the 1st quarter. Cetera Investment Advisers now owns 50,511 shares of the biotechnology company's stock valued at $1,002,000 after acquiring an additional 670 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of ADMA Biologics by 1.1% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 66,671 shares of the biotechnology company's stock valued at $1,323,000 after purchasing an additional 711 shares during the period. GF Fund Management CO. LTD. raised its stake in shares of ADMA Biologics by 21.9% in the first quarter. GF Fund Management CO. LTD. now owns 6,053 shares of the biotechnology company's stock worth $120,000 after purchasing an additional 1,089 shares during the last quarter. Journey Strategic Wealth LLC lifted its holdings in shares of ADMA Biologics by 6.6% during the first quarter. Journey Strategic Wealth LLC now owns 17,820 shares of the biotechnology company's stock worth $354,000 after purchasing an additional 1,102 shares during the period. Finally, KBC Group NV boosted its position in ADMA Biologics by 11.5% in the first quarter. KBC Group NV now owns 11,217 shares of the biotechnology company's stock valued at $223,000 after buying an additional 1,154 shares during the last quarter. Hedge funds and other institutional investors own 75.68% of the company's stock.

Insider Activity

In other news, Director Jerrold B. Grossman sold 10,000 shares of the firm's stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $21.31, for a total transaction of $213,100.00. Following the completion of the sale, the director owned 478,194 shares in the company, valued at $10,190,314.14. This trade represents a 2.05% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Steve Elms sold 194,749 shares of the company's stock in a transaction on Monday, June 16th. The shares were sold at an average price of $20.24, for a total value of $3,941,719.76. Following the completion of the transaction, the director directly owned 87,330 shares in the company, valued at approximately $1,767,559.20. This trade represents a 69.04% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 455,621 shares of company stock valued at $9,461,633 in the last 90 days. Company insiders own 3.50% of the company's stock.

ADMA Biologics Price Performance

Shares of ADMA Biologics stock traded up $0.70 during trading hours on Friday, reaching $17.80. 2,342,671 shares of the company's stock were exchanged, compared to its average volume of 3,444,757. The business has a fifty day moving average of $17.91 and a two-hundred day moving average of $18.89. The company has a market capitalization of $4.25 billion, a P/E ratio of 20.70 and a beta of 0.38. The company has a quick ratio of 2.78, a current ratio of 5.33 and a debt-to-equity ratio of 0.21. ADMA Biologics Inc has a 1 year low of $13.50 and a 1 year high of $25.67.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 earnings per share for the quarter, topping the consensus estimate of $0.14 by $0.01. ADMA Biologics had a return on equity of 41.01% and a net margin of 44.06%.The business had revenue of $121.98 million for the quarter, compared to analysts' expectations of $121.77 million. During the same period in the previous year, the firm posted $0.13 EPS. The business's revenue for the quarter was up 13.8% compared to the same quarter last year. As a group, research analysts predict that ADMA Biologics Inc will post 0.51 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ADMA has been the subject of a number of recent research reports. Wall Street Zen lowered shares of ADMA Biologics from a "hold" rating to a "sell" rating in a research report on Friday, May 9th. Raymond James Financial upped their price target on shares of ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a report on Thursday, May 8th. One equities research analyst has rated the stock with a Strong Buy rating and two have issued a Buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $27.67.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.